<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576390</url>
  </required_header>
  <id_info>
    <org_study_id>TBRI -Palonosetron</org_study_id>
    <nct_id>NCT04576390</nct_id>
  </id_info>
  <brief_title>Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing ERCP</brief_title>
  <official_title>Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing Endoscopic Retrograde Cholangio-Pancreatography ERCP: A Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theodor Bilharz Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Theodor Bilharz Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the effects of a single dose Ondansetron 4mg versus&#xD;
      Palonosetron 75mcg in the prophylaxis against early &amp; delayed postoperative nausea and&#xD;
      vomiting in the first 48 hours post-operatively in patients undergoing Endoscopic Retrograde&#xD;
      Cholangio-Pancreatography (ERCP) to determine the complete response, complete control and&#xD;
      failure rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Premedication will be omitted. Pre-operative baseline values of heart rate and blood pressure&#xD;
      will be recorded. On arrival in the operation theatre, the routine monitoring devices (ECG,&#xD;
      Pulse Oximetry &amp; Non Invasive Blood Pressure) will be applied and base line heart rate, blood&#xD;
      pressure (Systolic, diastolic and mean arterial blood pressure) and arterial Oxygen&#xD;
      saturation will be recorded.&#xD;
&#xD;
      After an intravenous line is secured, while pre-oxygenating the patient. Anaesthesia will be&#xD;
      induced using fentanyl 1-2 µg/kg and sodium propofol 1.5-2.5 mg/kg according to the patient&#xD;
      general condition and hemodynamics and intubation will be facilitated by using atracurium&#xD;
      besylate 0.5mg/kg.&#xD;
&#xD;
      Anaesthesia will be maintained with O2 in air (50%), sevoflurane (0.8-1.0 MAC). Muscle&#xD;
      relaxation will be maintained with boluses of atracurium besylate 0.1 mg/kg. Intermittent&#xD;
      positive pressure ventilation will be adjusted to maintain end tidal carbon dioxide between&#xD;
      30-35mm Hg. Intravenous crystalloids (3-4 ml/kg/hr) will infused during intra-operative and&#xD;
      immediate post-operative period. Intra-operatively, the following parameters will be&#xD;
      monitored: ECG, blood pressure, pulse rate, end tidal carbon dioxide (ET CO2) &amp; oxygen&#xD;
      saturation (SpO2). Diclofenac sodium 1mg/kg intramuscularly to protect against Post ERCP&#xD;
      Pancreatitis &amp; Paracetamol (1gm) intravenously will be administered 15 minutes before the end&#xD;
      of procedure followed by the administration of the anti-emetic prophylaxis according to group&#xD;
      allocation.&#xD;
&#xD;
      At the end, residual neuromuscular block will be antagonized using atropine and neostigmine&#xD;
      and trachea will be extubated after signs of adequate neuro-muscular reversal are achieved.&#xD;
      After extubation, patients will be transferred to the Post anaesthesia care unit where the&#xD;
      blood pressure, heart rate, respiratory rate and O2 saturation will be monitored continuously&#xD;
      every five minutes for 60 minutes.&#xD;
&#xD;
      If Visual Analogue Score (VAS) score is ≥3, rescue analgesia will be provided with Pethidine&#xD;
      in 10mg increments / 5minutes until the VAS score is less than 3.&#xD;
&#xD;
      Pain intensity will be assessed using VAS for the first 24 hours. Post-operative pain relief&#xD;
      will be provided Paracetamol (1gm) intravenously given regularly every 8 hours for the first&#xD;
      24 hours.&#xD;
&#xD;
      Any incidence of nausea, retching or vomiting and use of any rescue medication during the&#xD;
      first 24 hours at time interval of 0, 1/2, 1, 2, 6,12, 24 and 48 h will be noted, Nausea is&#xD;
      defined as the subjective sensation of an urge to vomit, in the absence of expulsive muscular&#xD;
      movements. Retching is defined as an unproductive effort to vomit. Vomiting is defined as the&#xD;
      forcible expulsion of the gastric contents through the mouth. Retching and vomiting will be&#xD;
      collectively termed emetic episodes.&#xD;
&#xD;
      Rescue anti-emetic therapy in the form of Metoclopramide 10 mg intravenously will be provided&#xD;
      for any patient suffering from an emetic episode as described above. The use of antiemetic&#xD;
      rescue medication will be recorded &amp; analysed.&#xD;
&#xD;
      Patients will stay at the hospital post ERCP according to the discretion of the treating&#xD;
      physician opinion, if any patient will be discharged before 48 hours, the data will be&#xD;
      collected by telephone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 24, 2020</start_date>
  <completion_date type="Anticipated">May 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of PONV</measure>
    <time_frame>During 24 hours post-operatively</time_frame>
    <description>Incidence of nausea, retching or vomiting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of PONV</measure>
    <time_frame>During 48 hours post-operatively</time_frame>
    <description>Incidence of nausea, retching or vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Responders</measure>
    <time_frame>During 48 hours postoperatively</time_frame>
    <description>Number of patients has no rescue medication and no emesis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete control</measure>
    <time_frame>During 48 hours postoperatively</time_frame>
    <description>Number of patients has no rescue medication, no emesis, no more than mild nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failed prophylaxis</measure>
    <time_frame>During 48 hours postoperatively</time_frame>
    <description>Number of patients with episode of emesis and needs rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rescue anti-emetics or emesis</measure>
    <time_frame>Time in minutes during 48 hours postoperatively</time_frame>
    <description>Time until patient takes antiemetic or emesis occurs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Antiemetic</condition>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Group O</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On the day of procedure, the recruited patients in Group O will be given Ondansetron 4 mg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care &amp; will label the syringes as antiemetic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On the day of procedure, the recruited patients in Group P will be given Palonosetron 75 mcg diluted for up to 5ml using normal saline by a colleague not participating to the study or the patient care &amp; will label the syringes as antiemetic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 4 mg</intervention_name>
    <description>Antiemetic drug</description>
    <arm_group_label>Group O</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron 75 mcg</intervention_name>
    <description>Antiemetic drug</description>
    <arm_group_label>Group P</arm_group_label>
    <other_name>Aloxi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 18-60 years of age&#xD;
&#xD;
          -  American Society of Anaesthesiologists physical status (ASA) grade I-II&#xD;
&#xD;
          -  1 - 2 Risk factor for PONV according to Apfel Score&#xD;
&#xD;
             o Apfel Score includes 4 points : Female gender, history of PONV and/or motion&#xD;
             sickness, non-smoking status, and post-operative use of opioids , the risk of PONV is&#xD;
             10%, 20%, 40%,60% or 80% respectively&#xD;
&#xD;
          -  Undergoing elective ERCP.&#xD;
&#xD;
          -  Having provided written informed consent signed by patient or guardian.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to any drug being used in the study&#xD;
&#xD;
          -  ASA III-IV&#xD;
&#xD;
          -  History of vomiting, retching, nausea or antiemetics use in the 24 hours prior to day&#xD;
             of procedure&#xD;
&#xD;
          -  Patients receiving steroids, prokinetics, or antacids intake in the previous 48 hours&#xD;
&#xD;
          -  Patients with significant gastro-oesophageal disease&#xD;
&#xD;
          -  Menstruating, lactating or pregnant females&#xD;
&#xD;
          -  History of alcohol or substance abuse&#xD;
&#xD;
          -  Significant systemic disease of the liver, kidneys, heart, lungs, Cancer and or&#xD;
             diabetes mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar M. Abou-Hashim, residant</last_name>
    <role>Study Chair</role>
    <affiliation>Theodor Bilharz Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yahia M. Hammad, Lecteurer</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mounis A. Sedira, Prof.</last_name>
    <phone>00201110081661</phone>
    <email>mounis200@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed M. Elbadawy, Prof.</last_name>
    <phone>00201005620903</phone>
    <email>badawykhalil@gmail.com</email>
  </overall_contact_backup>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Theodor Bilharz Research Institute</investigator_affiliation>
    <investigator_full_name>Hanan Farouk Khafagy</investigator_full_name>
    <investigator_title>Professor doctor</investigator_title>
  </responsible_party>
  <keyword>Palonosetron</keyword>
  <keyword>Ondansetron</keyword>
  <keyword>PONV</keyword>
  <keyword>ERCP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

